Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | UBE2I | P63279 | 1/20 | 0.52 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.52 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16266078 | 0.83 | LMNA (0.71) | LMNAPKMALDH1A1MAPK14KDM4E | |
| SCHEMBL24254500 | 0.79 | ALDH1A1 (0.78) | LMNAPKMALDH1A1MAPK14KDM4E | |
| SCHEMBL24254495 | 0.77 | ALDH1A1 (1.00) | LMNAPKMALDH1A1MAPK14KDM4E | |
| SCHEMBL16266077 | 0.76 | ALDH1A1 (0.56) | LMNAPKMALDH1A1KDM4ENPSR1 | |
| SCHEMBL16266072 | 0.74 | ALDH1A1 (0.65) | LMNAPKMALDH1A1KDM4ENPSR1 | |
| SCHEMBL24254509 | 0.73 | ALDH1A1 (0.69) | LMNAPKMALDH1A1KDM4EGAA | |
| SCHEMBL26188047 | 0.72 | ALDH1A1 (0.67) | LMNAPKMALDH1A1GAAL3MBTL1 | |
| SCHEMBL16266127 | 0.72 | ALDH1A1 (0.69) | LMNAALDH1A1KDM4EGAANPSR1 | |
| SCHEMBL23057067 | 0.71 | ALDH1A1 (0.66) | LMNAPKMALDH1A1KDM4EGAA | |
| SCHEMBL16266075 | 0.71 | NPSR1 (0.55) | LMNAPKMALDH1A1MAPK14KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212290-B1 | ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMA (US) | 2014-12-03 | — | — | EP | claimed |
| EP-2004596-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2008-12-24 | — | — | EP | claimed |
| WO-2007120647-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-25 | — | — | WO | claimed |
| US-20070238733-A1 | Drugs for various disorders such as sodium channel modulators, cardiovascular disorders, antiarrhythmia agents ar nervous system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-11 | — | — | US | claimed |
| US-8841483-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2004596-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120647-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070238733-A1 | Drugs for various disorders such as sodium channel modulators, cardiovascular disorders, antiarrhythmia agents ar nervous system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238733-A1 | Drugs for various disorders such as sodium channel modulators, cardiovascular disorders, antiarrhythmia agents ar nervous system disorders | KCNH1, SCN5A, CACNA1A | LMNA 836/4885PKM 1734/4885ALDH1A1 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.